RxDoctor Payments Data

Michael Bergman, MD

Internal Medicine · Miami Beach, FLNPI 1659437572

Payments from drug & device makers

$871in general payments, 2019–2025

Across 34 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$332
  • Janssen Products, LP$199
  • Gilead$171
  • Merck$75
  • Novartis$54
  • Exact Sciences$22
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$67277%
  • Education$19923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$871 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,769
Medicare patients
40
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala138$558,468
JulucaDolutegravir/Rilpivirine136$470,661
TriumeqAbacavir/Dolutegravir/Lamivudi47$187,067
TivicayDolutegravir Sodium57$129,843
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf19$114,213
DovatoDolutegravir Sodium/Lamivudine34$104,395
CabenuvaCabotegravir/Rilpivirine11$72,952
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$65,935
PrezcobixDarunavir/Cobicistat26$65,427
DescovyEmtricitabine/Tenofov Alafenam12$29,074
DelstrigoDoravirine/Lamivu/Tenofov Diso11$28,970
EliquisApixaban27$21,744
IsentressRaltegravir Potassium11$21,525
FarxigaDapagliflozin Propanediol21$12,249
JardianceEmpagliflozin15$12,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato, Cabenuva$332$964,917285 claims
GileadBiktarvy, Genvoya, Descovy$171$653,476165 claims
Janssen Products, LPSymtuza$199$114,21319 claims
Johnson & JohnsonPrezcobix$18$65,42726 claims
MerckDelstrigo, Isentress$75$50,49622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →